What is the semaglutide dose schedule for weight loss in the UK?

What does the full semaglutide dose schedule actually look like?

The licensed UK schedule for Wegovy runs in five steps. You begin at 0.25 mg weekly. After four weeks, your prescriber moves you to 0.5 mg, then 1.0 mg, then 1.7 mg, and finally to the 2.4 mg maintenance dose. That's a minimum of around five months from first injection to full maintenance, provided your body tolerates each step without significant side effects prompting a pause or a slower climb.

The full Wegovy dose range also now includes 7.2 mg, which the MHRA approved on 14 April 2026. That higher dose is delivered through a dedicated single-dose pen and is licensed for adults with a BMI of 30 or above, a separate tier rather than a routine next step for everyone. The titration path to 7.2 mg still begins at 0.25 mg; the prescriber assesses whether the higher ceiling is appropriate for you individually.

A question our prescribers hear regularly: can I go faster if I feel fine? The short answer is no. The stepped schedule exists to reduce gastrointestinal side effects (nausea in particular) not to delay results. Skipping steps is not supported by the licensed dosing structure, and any adjustment to your semaglutide dosing sits with your prescriber and the Patient Information Leaflet, not with general guidance.

The NHS medicines page for semaglutide covers the schedule and what to do if a dose is missed, always a better reference for individual decisions than any content page.

Why does the starting dose feel like it's doing nothing?

0.25 mg is a tolerability dose. Its job is to settle your system and reduce the chance that the first few weeks feel miserable with nausea or vomiting. The therapeutic weight-loss effect builds through the mid-range doses and becomes pronounced at 1.7 mg and 2.4 mg. So if your first four weeks feel underwhelming, that's normal, the schedule is working as intended.

For context on results, the STEP 1 trial, published in the New England Journal of Medicine, found an average weight reduction of around 15% over 68 weeks at the 2.4 mg dose, in adults with obesity without diabetes. Those figures come from people completing a full titration, not from the first pen. If you're curious about what the 2 mg range involves, that's covered separately.

One practical note on timing: if you start treatment in December and your dose increase lands over a bank holiday week, your pen delivery schedule may shift by a working day. It's worth factoring that into repeat orders (payday, bank holidays, a two-week holiday) so you're not caught without stock mid-titration. A prescriber can advise if an injection is a couple of days late.

People sometimes ask about how semaglutide dose translates to volume in the pen. The pre-filled Wegovy pen dials the dose for you, so the ml figure is handled by the device rather than the patient, useful to understand, but not something you typically need to calculate.

What if 2.4 mg isn't producing results, is a higher semaglutide dose an option?

Until recently, 2.4 mg was the ceiling for licensed weight-loss treatment in the UK. The approval of the 7.2 mg Wegovy pen changes that for eligible patients. Trials reported an average weight loss of around 20.7% over 72 weeks at 7.2 mg, which begins to close the gap on the results seen with tirzepatide (Mounjaro) in head-to-head studies. Full details on the 7.2 mg approval and what it means are available if you want the regulatory background.

NICE's appraisal of semaglutide (TA875) recommends its use within specialist weight management services, with the caveat that treatment should be reviewed if less than 5% body weight is lost after six months at the maintenance dose. That review is a clinical conversation, not an automatic stop, and it's part of why ongoing prescriber oversight matters throughout treatment, not just at the start.

Cost is a real consideration at this stage of treatment. Prices vary by dose and by provider. If you're weighing up whether the investment makes sense, the Wegovy pricing context page gives an honest picture of what drives the cost and what a legitimate private prescription typically includes, without suggesting cheapest is a useful target.

How does semaglutide dosing for weight loss differ from its use in diabetes?

Ozempic is also semaglutide, but its licensed dose range runs differently and its indication is type 2 diabetes. The weight-management licence belongs to Wegovy, with the 0.25 mg to 2.4 mg (now 7.2 mg) schedule described above. They are not interchangeable from a prescribing or regulatory standpoint, what Wegovy is and how it differs covers this distinction if needed.

The same logic applies to Rybelsus, the oral semaglutide tablet approved for type 2 diabetes: its 3 mg, 7 mg and 14 mg steps are not weight-management doses. The Wegovy tablet (also oral semaglutide, approved for weight loss in the UK in June 2026) uses a completely different dose ladder: 1.5 mg, 4 mg, 9 mg, and a 25 mg maintenance dose. Mixing up these two products' dose ranges is an easy mistake, they share a molecule but sit in entirely separate clinical pathways.

If you're at the point of thinking about whether semaglutide or another licensed treatment fits your situation, the treatment overview gives a clear comparison. Deciding which dose ladder suits you is a clinical question, and it starts with a prescriber looking at your full picture.